Theratechnologies Inc. (THTX)
USD 1.53
(3.04%)
USD 1.53
(3.04%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 6.06 Million USD | -69.19% |
| 2022 | 19.68 Million USD | -32.44% |
| 2021 | 29.14 Million USD | 15.89% |
| 2020 | 25.14 Million USD | 20.14% |
| 2019 | 20.92 Million USD | 88.77% |
| 2018 | 11.08 Million USD | 53.16% |
| 2017 | 7.23 Million USD | -20.74% |
| 2016 | 9.13 Million USD | -4.19% |
| 2015 | 9.53 Million USD | 2.44% |
| 2014 | 9.3 Million USD | -10.36% |
| 2013 | 10.38 Million USD | -19.36% |
| 2012 | 12.87 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 6.29 Million USD | 3.76% |
| 2024 Q3 | 5.98 Million USD | 8.24% |
| 2024 Q2 | 5.53 Million USD | -12.09% |
| 2023 Q3 | 6.72 Million USD | -26.62% |
| 2023 Q1 | 15.11 Million USD | -23.25% |
| 2023 Q4 | 6.06 Million USD | -9.77% |
| 2023 FY | 6.06 Million USD | -69.19% |
| 2023 Q2 | 9.16 Million USD | -39.36% |
| 2022 Q2 | 24.97 Million USD | -4.43% |
| 2022 Q4 | 19.68 Million USD | -14.92% |
| 2022 Q3 | 23.14 Million USD | -7.35% |
| 2022 FY | 19.68 Million USD | -32.44% |
| 2022 Q1 | 26.13 Million USD | -10.32% |
| 2021 FY | 29.14 Million USD | 15.89% |
| 2021 Q3 | 27.29 Million USD | -4.5% |
| 2021 Q1 | 27.34 Million USD | 8.75% |
| 2021 Q4 | 29.14 Million USD | 6.77% |
| 2021 Q2 | 28.57 Million USD | 4.51% |
| 2020 Q1 | 20.67 Million USD | -1.24% |
| 2020 FY | 25.14 Million USD | 20.14% |
| 2020 Q2 | 24.73 Million USD | 19.67% |
| 2020 Q3 | 25.66 Million USD | 3.78% |
| 2020 Q4 | 25.14 Million USD | -2.04% |
| 2019 Q3 | 12.86 Million USD | -0.01% |
| 2019 Q1 | 11.5 Million USD | 3.77% |
| 2019 Q2 | 12.86 Million USD | 11.82% |
| 2019 FY | 20.92 Million USD | 88.77% |
| 2019 Q4 | 20.92 Million USD | 62.74% |
| 2018 Q2 | 8.57 Million USD | 16.37% |
| 2018 FY | 11.08 Million USD | 53.16% |
| 2018 Q1 | 7.36 Million USD | 1.8% |
| 2018 Q4 | 11.08 Million USD | 29.16% |
| 2018 Q3 | 8.58 Million USD | 0.07% |
| 2017 Q4 | 7.23 Million USD | -12.6% |
| 2017 FY | 7.23 Million USD | -20.74% |
| 2017 Q3 | 8.28 Million USD | -6.16% |
| 2017 Q2 | 8.82 Million USD | 1.84% |
| 2017 Q1 | 8.66 Million USD | -5.11% |
| 2016 Q2 | 9.64 Million USD | 7.96% |
| 2016 FY | 9.13 Million USD | -4.19% |
| 2016 Q4 | 9.13 Million USD | -5.11% |
| 2016 Q3 | 9.62 Million USD | -0.16% |
| 2016 Q1 | 8.92 Million USD | -6.33% |
| 2015 Q3 | 9.64 Million USD | -2.64% |
| 2015 FY | 9.53 Million USD | 2.44% |
| 2015 Q2 | 9.9 Million USD | 5.21% |
| 2015 Q4 | 9.53 Million USD | -1.13% |
| 2015 Q1 | 9.41 Million USD | 1.15% |
| 2014 Q3 | 9.65 Million USD | 3.42% |
| 2014 Q2 | 9.33 Million USD | 3.4% |
| 2014 Q1 | 9.02 Million USD | -13.06% |
| 2014 FY | 9.3 Million USD | -10.36% |
| 2014 Q4 | 9.3 Million USD | -3.59% |
| 2013 Q2 | 12.33 Million USD | -4.9% |
| 2013 FY | 10.38 Million USD | -19.36% |
| 2013 Q4 | 10.38 Million USD | -3.55% |
| 2013 Q3 | 10.76 Million USD | -12.76% |
| 2013 Q1 | 12.97 Million USD | 0.77% |
| 2012 FY | 12.87 Million USD | 0.0% |
| 2012 Q4 | 12.87 Million USD | -8.17% |
| 2012 Q2 | 13.78 Million USD | 1.01% |
| 2012 Q1 | 13.65 Million USD | 36.43% |
| 2012 Q3 | 14.01 Million USD | 1.67% |
| 2011 Q1 | 4.71 Million USD | 11.42% |
| 2011 Q4 | 10 Million USD | -7.58% |
| 2011 Q3 | 10.82 Million USD | 35.26% |
| 2011 Q2 | 8 Million USD | 69.66% |
| 2010 Q4 | 4.23 Million USD | -2.07% |
| 2010 Q1 | 2.14 Million USD | 1.8% |
| 2010 Q2 | 4.26 Million USD | 98.97% |
| 2010 Q3 | 4.32 Million USD | 1.47% |
| 2009 Q4 | 2.1 Million USD | 44.54% |
| 2009 Q1 | 1.25 Million USD | 418.04% |
| 2009 Q2 | 1.46 Million USD | 16.47% |
| 2009 Q3 | 1.45 Million USD | -0.48% |
| 2008 Q3 | 240.04 Thousand USD | -59.75% |
| 2008 Q1 | 1.18 Million USD | -43.88% |
| 2008 Q2 | 596.39 Thousand USD | -49.61% |
| 2008 Q4 | 242.37 Thousand USD | 0.97% |
| 2007 Q2 | 2.44 Million USD | 31.63% |
| 2007 Q3 | 2.26 Million USD | -7.42% |
| 2007 Q1 | 1.85 Million USD | 149.55% |
| 2007 Q4 | 2.1 Million USD | -6.87% |
| 2006 Q2 | 2.17 Million USD | 21.69% |
| 2006 Q1 | 1.78 Million USD | 8.18% |
| 2006 Q3 | 2.04 Million USD | -5.8% |
| 2006 Q4 | 744.63 Thousand USD | -63.64% |
| 2005 Q3 | 2.23 Million USD | 6.82% |
| 2005 Q4 | 1.65 Million USD | -25.95% |
| 2005 Q2 | 2.08 Million USD | 66.42% |
| 2005 Q1 | 1.25 Million USD | -3.39% |
| 2004 Q1 | 681.25 Thousand USD | -10.68% |
| 2004 Q2 | 663.53 Thousand USD | -2.6% |
| 2004 Q3 | 1.05 Million USD | 59.24% |
| 2004 Q4 | 1.29 Million USD | 22.91% |
| 2003 Q2 | 2.39 Million USD | 0.97% |
| 2003 Q3 | 2.26 Million USD | -5.55% |
| 2003 Q1 | 2.37 Million USD | 86.42% |
| 2003 Q4 | 762.71 Thousand USD | -66.31% |
| 2002 Q4 | 1.27 Million USD | -13.63% |
| 2002 Q1 | 966.5 Thousand USD | 32.31% |
| 2002 Q2 | 1.15 Million USD | 19.57% |
| 2002 Q3 | 1.47 Million USD | 27.6% |
| 2001 Q1 | 568.79 Thousand USD | 15.82% |
| 2001 Q4 | 730.47 Thousand USD | -16.58% |
| 2001 Q3 | 875.67 Thousand USD | 4.69% |
| 2001 Q2 | 836.41 Thousand USD | 47.05% |
| 2000 Q1 | 68.91 Thousand USD | 1.48% |
| 2000 Q4 | 491.11 Thousand USD | 152.92% |
| 2000 Q3 | 194.18 Thousand USD | -3.02% |
| 2000 Q2 | 200.22 Thousand USD | 190.53% |
| 1999 Q4 | 67.9 Thousand USD | 1.49% |
| 1999 Q1 | 198.87 Thousand USD | -23.63% |
| 1999 Q3 | 66.9 Thousand USD | -50.67% |
| 1999 Q2 | 135.64 Thousand USD | -31.8% |
| 1998 Q2 | 68.65 Thousand USD | -2.29% |
| 1998 Q3 | 126.55 Thousand USD | 84.33% |
| 1998 Q4 | 260.41 Thousand USD | 105.78% |
| 1998 Q1 | 70.26 Thousand USD | -0.01% |
| 1997 Q4 | 70.27 Thousand USD | -51.19% |
| 1997 Q1 | 219.2 Thousand USD | 0.0% |
| 1997 Q3 | 143.98 Thousand USD | -33.85% |
| 1997 Q2 | 217.67 Thousand USD | -0.7% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Cosmos Health Inc. | 4.78 Million USD | -26.664% |
| Safety Shot Inc | 1.86 Million USD | -224.446% |
| Bright Green Corporation | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 96.012% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 94.545% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 10.386% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 81.238% |
| Dynavax Technologies Corporation | 53.29 Million USD | 88.617% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 90.756% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 47.918% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 94.187% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -5.776% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -5.776% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -649.114% |
| Journey Medical Corporation | 10.2 Million USD | 40.564% |
| Alpha Teknova, Inc. | 11.59 Million USD | 47.68% |
| Procaps Group, S.A. | 96.83 Million USD | 93.736% |
| Harrow Health, Inc. | 10.86 Million USD | 44.18% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -123.097% |
| Biofrontera Inc. | 10.9 Million USD | 44.389% |
| DURECT Corporation | 2.21 Million USD | -173.366% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 92.164% |
| Cronos Group Inc. | 30.33 Million USD | 80.006% |
| OptiNose, Inc. | 8.05 Million USD | 24.665% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -606599900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -6.439% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 78.53% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -126.587% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -31.602% |
| Radius Health, Inc. | 278.64 Million USD | 97.823% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -81.439% |
| ProPhase Labs, Inc. | 3.84 Million USD | -57.928% |
| Phibro Animal Health Corporation | 265.91 Million USD | 97.719% |
| Procaps Group S.A. | 96.83 Million USD | 93.736% |
| Alvotech | 74.43 Million USD | 91.85% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.825% |
| Rockwell Medical, Inc. | 5.87 Million USD | -3.321% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 51.983% |
| SIGA Technologies, Inc. | 64.21 Million USD | 90.554% |
| Tilray Brands, Inc. | 252.08 Million USD | 97.594% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 84.827% |
| Shineco, Inc. | 1.58 Million USD | -281.864% |
| PetIQ, Inc. | 159.3 Million USD | 96.192% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 4070.467% |
| Incannex Healthcare Limited | -10.01 Million USD | 160.569% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 84.162% |
| Alimera Sciences, Inc. | 1.87 Million USD | -222.831% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 83.904% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -276.679% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -35.311% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -2284.884% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 41.561% |
| Hempacco Co., Inc. | 2.54 Million USD | -138.572% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 91.85% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 87.308% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 90.526% |
| Currenc Group, Inc. | 732.91 Thousand USD | -727.658% |
| Kamada Ltd. | 87.74 Million USD | 93.087% |
| Indivior PLC | 141.79 Million USD | 95.722% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -1158.924% |
| Flora Growth Corp. | 8.5 Million USD | 28.702% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -2284.884% |
| Evolus, Inc. | 10.99 Million USD | 44.845% |
| HUTCHMED (China) Limited | 50.25 Million USD | 87.93% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 94.268% |
| Akanda Corp. | 1.28 Million USD | -371.367% |